ArticleCureus2024
Extra-medullary Plasmacytomas: A Case Series of Rare Hematological Tumors.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solitary plasmacytoma is a rare malignant tumor belonging to the family of plasma cell proliferation. It accounts for a small portion of plasma cell tumors and remains a rare condition. We report three cases of rare extraosseous plasmacytomas in young patients. Case 1 describes a 55-year-old patient with multiple cutaneous plasmacytomas who underwent a watchful waiting approach. Case 2 discusses a 44-year-old patient with nasal plasmacytoma who was successfully treated with exclusive radiotherapy. Case 3 reports on a 52-year-old patient with a solitary ovarian plasmacytoma who underwent surgical resection and did not receive adjuvant treatment due to complete resection. The patients did not have multiple myeloma and had different treatment approaches based on the location and extent of the plasmacytoma. Local recurrence and progression to multiple myeloma may occur, justifying prolonged and rigorous monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.